Therapeutic advances in reproductive health最新文献

{"title":"Association between pathological positivity rate of endometriosis, demographics, and concomitant gynecological conditions.","authors":"Daniela Moiño, Papri Sarkar, Maha Al Jumaily, Samantha Malak, Jean Paul Tanner, Emad Mikhail","doi":"10.1177/26334941241242351","DOIUrl":"https://doi.org/10.1177/26334941241242351","url":null,"abstract":"<p><strong>Background: </strong>To date, there remains a paucity of present-day literature on the topic of demographics and the biopsy-proven pathological positivity rate of endometriosis.</p><p><strong>Objective: </strong>The goal of this study was to explore the association between patients' demographics and other concomitant gynecological conditions or procedures and the pathological positivity rate of excision of endometriosis.</p><p><strong>Design: </strong>Retrospective cohort study.</p><p><strong>Methods: </strong>All women >18 years old who underwent laparoscopic surgery for endometriosis at a tertiary care hospital from October 2011 to October 2020. Women were classified into two groups: (1) Study group: women with >80% pathological positivity rate of endometriosis and (2) Control group: women with <80% pathological positivity rate.</p><p><strong>Results: </strong>A total of 401 women were included in the analysis. No difference was noted in the 80% pathological positivity rate based on body mass index [BMI; 68.7% in normal BMI <i>versus</i> 80% in underweight, <i>versus</i> 74.5% in overweight, and 74.1% in obese patients (<i>p</i> = 0.72)]. The percentage of patients reaching 80% pathological positivity of endometriosis was lower in women who had undergone previous laparoscopy for endometriosis compared to surgery naïve women (66.5% <i>versus</i> 76.5%, <i>p</i> = 0.03). In addition, a higher percentage of women who underwent concomitant hysterectomy (83.5% <i>versus</i> 68.8% for non-hysterectomy, <i>p</i> = 0.005) or bilateral oophorectomy (92.7% <i>versus</i> 70.0% for non-oophorectomy, <i>p</i> = 0.002) reached 80% pathological positivity. Women with an associated diagnosis of fibroids (79.7% <i>versus</i> 70.5%) or adenomyosis (76.4% <i>versus</i> 71.7%) were more likely to reach 80% pathological positivity compared to women without any other coexisting pathology; however, the observed differences were not statistically significant. After applying a log-binomial regression model, compared to White non-Hispanics, Hispanic patients were 30% less likely to reach 80% positivity (RR: 0.70, 95% CI: 0.49-1.02), although not statistically significant.</p><p><strong>Conclusion: </strong>No significant racial difference was found when comparing the rates of 80% pathological positivity of suspected endometriosis lesions among groups. Endometriosis pathological positivity rate was unaffected by patients' BMI and the presence of concomitant pathologies. In addition, prior laparoscopic surgery for endometriosis might cause tissue changes that result in a decrease in the observed pathological positivity rate of endometriosis lesions during subsequent surgeries.</p>","PeriodicalId":75219,"journal":{"name":"Therapeutic advances in reproductive health","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-04-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11015736/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140862928","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Barriers to fertility preservation access in transgender and gender diverse adolescents: a narrative review.","authors":"Ashni S Nadgauda, Samantha Butts","doi":"10.1177/26334941231222120","DOIUrl":"10.1177/26334941231222120","url":null,"abstract":"<p><p>Fertility preservation (FP) involves the cryopreservation of gametes, embryos, and/or gonadal tissue oocytes, for future use in family building. FP as part of a comprehensive approach to care of transgender and gender diverse (TGD) individuals is an understudied topic. Current evidence indicates that gender affirming therapies may increase the risk for infertility. As a result, TGD individuals, including adolescents, should receive counseling regarding FP prior to beginning gender affirming treatment. Many barriers exist to TGD adolescents receiving FP counseling and undergoing FP if desired. The objective of this narrative review is to summarize the literature regarding the desire for FP in TGD adolescents, the barriers to TGD adolescents in accessing of FP, and to discuss potential interventions for alleviation of such barriers. A literature search using the following Medical Subject Headings search terms: 'transgender persons' and 'fertility preservation' and 'adolescents' was conducted <i>via</i> searching PubMed. Additional articles were located <i>via</i> reference review. Included articles consist of qualitative and quantitative research and society guidelines. Articles from inception to 1st July 2023 were included. The results of the literature search have been summarized into the format of a narrative review. Key barriers to FP for TGD adolescents include inconsistencies in form and timing of counseling, potential worsening of gender dysphoria with FP treatment, high cost of treatment, limited research on FP outcomes, and legal barriers. Intersectionality between gender identity and other forms of minority status can compound these barriers to FP and healthcare in general. Barriers to TGD adolescents accessing FP are significant. Increased research is needed upon methods to mitigate these barriers. Solutions include increasing uniformity and timing of FP counseling by varying health care providers, advocacy efforts to mitigate legal and financial barriers, increased research efforts in FP outcomes, and increased cultural competency in clinics offering FP care to TGD adolescents.</p>","PeriodicalId":75219,"journal":{"name":"Therapeutic advances in reproductive health","volume":null,"pages":null},"PeriodicalIF":3.1,"publicationDate":"2024-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10826369/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139643540","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of efficacy between levonorgestrel intrauterine system and dienogest in adenomyosis: a randomized clinical trial.","authors":"Satish Choudhury, Saubhagya Kumar Jena, Subarna Mitra, Biswa Mohan Padhy, Sudipta Mohakud","doi":"10.1177/26334941241227401","DOIUrl":"10.1177/26334941241227401","url":null,"abstract":"<p><strong>Background: </strong>Medical management of adenomyosis is an emerging perspective in modern gynecology. Though levonorgestrel intrauterine system (LNG-IUS) and dienogest (DNG) effectively relieve symptoms in adenomyosis, neither has been approved for the same indication. Our study aims to compare the efficacy and safety of these progestins in treating adenomyosis.</p><p><strong>Objective: </strong>To study the efficacy and safety of LNG-IUS <i>versus</i> DNG in patients with symptomatic adenomyosis.</p><p><strong>Design: </strong>Open-labeled, parallel, single-centered, randomized clinical trial.</p><p><strong>Methods: </strong>Patients with adenomyosis-associated pain with or without abnormal uterine bleeding were randomly allocated to either LNG-IUS group or DNG group. The primary outcome was a reduction in painful symptoms after 12 weeks of treatment measured by visual analog scale (VAS) score. Changes in menstrual blood loss (MBL), improvement in quality of life (QoL), and adverse drug reactions were also analyzed.</p><p><strong>Results: </strong>The VAS score significantly decreased from baseline in both groups. The baseline and post-treatment VAS scores in the LNG-IUS group were 6.41 ± 1.07 and 3.41 ± 1.04 (<i>p</i> = <0.001) and in the DNG group, were 6.41 ± 0.95 and 3.12 ± 1.40 (<i>p</i> = <0.001), respectively. A significantly greater proportion of patients in the LNG-IUS group experienced lighter MBL as compared to the DNG group [27/30 (90%) in the LNG-IUS group <i>versus</i> 17/22 (77.2%) in the DNG group (<i>p</i> = 0.006)]. Both the groups had improvement in QOL scores calculated by the World Heath Organisation QOL scale (WHOQOL BREF) questionnaire; however, it was more pronounced in the DNG group [(28.76 ± 30.47 in the LNG-IUS group <i>versus</i> 48.26 ± 44.91 in the DNG group (<i>p</i> = 0.04)]. Both the agents were safe as there were no reported major adverse drug reactions.</p><p><strong>Conclusion: </strong>DNG can be an effective and safe alternative to LNG-IUS for the medical management of adenomyosis.</p><p><strong>Trial registration: </strong>The trial was prospectively registered at the clinical trial registry - India (CTRI) vide CTRI number CTRI/2020/05/025186.</p>","PeriodicalId":75219,"journal":{"name":"Therapeutic advances in reproductive health","volume":null,"pages":null},"PeriodicalIF":3.1,"publicationDate":"2024-01-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10812097/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139572304","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ethnic disparities in the incidence of gynecologic malignancies among Israeli Women of Arab and Jewish Ethnicity: a 10-year study (2010-2019).","authors":"Roie Alter, Adiel Cohen, Paul-Adrien Guigue, Raanan Meyer, Gabriel Levin","doi":"10.1177/26334941231209496","DOIUrl":"10.1177/26334941231209496","url":null,"abstract":"<p><strong>Background: </strong>Ethnic disparities in healthcare outcomes persist, even when populations share the same environmental factors and healthcare infrastructure. Gynecologic malignancies are a significant health concern, making it essential to explore how these disparities manifest in terms of their incidence among different ethnic groups.</p><p><strong>Objective: </strong>To investigate ethnic disparities in the incidence of gynecologic malignancies incidence among Israeli women of Arab and Jewish ethnicity.</p><p><strong>Design: </strong>Our research employs a longitudinal, population-based retrospective cohort design.</p><p><strong>Method: </strong>Data on gynecologic cancer diagnoses among the Israeli population from 2010 to 2019 was obtained from a National Registry. Disease incidence rates and age standardization were calculated. A comparison between Arab and Jewish patients was performed, with Poisson regression models being used to analyze significant rate changes.</p><p><strong>Results: </strong>Among Jewish women, the age-standardized ratio (ASR) for gynecologic malignancies decreased from 288 to 251 (<i>p</i> < 0.001) between 2014 and 2019. However, there was no significant change in the ASR among Arab women during the same period, with rates going from 192 to 186 (<i>p</i> = 0.802). During the study period, the incidence of ovarian cancer decreased significantly among Jewish women (<i>p</i> = 0.042), while the rate remained stable among Arab women (<i>p</i> = 0.102). A similar trend was observed for uterine cancer. The ASR of CIN III (Cervical Intraepithelial Neoplasia Grade 3) in Jewish women notably increased from 2017 to 2019, with an annual growth rate of 43.3% (<i>p</i> < 0.001). A similar substantial rise was observed among Arab women, with an annual growth rate of 40.5% (<i>p</i> < 0.001). In contrast, the incidence of invasive cervical cancer remained stable from 2010 to 2019 among women of both ethnic backgrounds.</p><p><strong>Conclusion: </strong>Our findings indicate that Arab women in Israel have a lower incidence rate of gynecologic cancers, warranting further investigation into protective factors. Both ethnic groups demonstrate effective utilization of cervical screening.</p>","PeriodicalId":75219,"journal":{"name":"Therapeutic advances in reproductive health","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10757790/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139076101","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Refusal of the hospitalization: a distressed dilemma in obstetric practice.","authors":"Canan Unal, Erdem Fadiloglu, Murat Cagan, Gunel Ziyadova, Esra Kaya, Atakan Tanacan, Mehmet Sinan Beksac","doi":"10.1177/26334941231216531","DOIUrl":"10.1177/26334941231216531","url":null,"abstract":"<p><strong>Background: </strong>Pregnant women are a special population in which hospitalizations are more recommended due to physiological changes mimicking pathologies and medico-legal concerns.</p><p><strong>Objectives: </strong>We aimed to assess the obstetric outcomes of expectant mothers who were admitted to the obstetrics emergency outpatient clinic and declined the hospitalization advised by doctors. Additionally, we examined the appropriateness of physicians' recommendations.</p><p><strong>Design: </strong>We have retrospectively evaluated the patients admitted to the 'Obstetric Emergency Outpatient Clinic' and refused hospitalization between 1 January 2019 and 31 December 2019.</p><p><strong>Methods: </strong>Cases were classified into three groups based on the trimester, considering the substantial variation between complaints and complications in each trimester. The complaints of pregnant women were categorized as psychosocial causes, obstetric complications, maternal systemic complaints, and suspicion of labor. We evaluated the compatibility of the hospitalization decision with the pregnancy outcome of patients.</p><p><strong>Results: </strong>A total of 958 pregnant women were included in the study. Leading causes for admissions were obstetric complications, maternal systemic complaints, and suspicion of labor in first, second, and third trimesters, respectively. Psychosocial causes were mostly observed in the second trimester. Readmission to the hospital within a week was highest in the third trimester group. According to pregnancy outcomes, 12.5% (94/753) of our recommendations were appropriate in all trimesters.</p><p><strong>Conclusion: </strong>Obstetricians seem overcautious in managing obstetric patients and willing to offer hospitalization more often than the actual requirements.</p>","PeriodicalId":75219,"journal":{"name":"Therapeutic advances in reproductive health","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-12-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10752054/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139049905","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intralipid infusion therapy as an adjunct treatment in women experiencing adenomyosis-related infertility.","authors":"James Henshaw, Kelton Tremellen","doi":"10.1177/26334941231181258","DOIUrl":"10.1177/26334941231181258","url":null,"abstract":"<p><strong>Background: </strong>Currently, there is some evidence that adenomyosis patients using gonadotropin-releasing hormone (GnRH) agonist long downregulation (LDR) prior to embryo transfer may improve in vitro fertilization (IVF) success rate, but not to the baseline expected success where there is no adenomyosis. Given the association between adenomyosis and an aberrant endometrial immune environment, many physicians also use prednisolone or Intralipid adjuvant treatments in combination with GnRH agonist therapy, despite neither being of proven benefit.</p><p><strong>Objective: </strong>The purpose of this study was to investigate whether the addition of prednisolone or Intralipid immune therapy to GnRH agonist LDR improves fertility outcomes in patients with adenomyosis.</p><p><strong>Methods: </strong>This is a retrospective cohort study of 116 consecutive adenomyosis patients who underwent their first transfer of a genetically screened euploid embryo between January 2019 and December 2020 at a private IVF clinic.</p><p><strong>Results: </strong>There was no difference in maternal age, body mass index, number of embryo's transferred and gravidity or parity among the three treatment groups. Patients who received Intralipid had a poorer prognosis with a longer duration of infertility (4 years) and a higher number of previous embryo transfers (ETs, 5 previous ETs) compared to the comparison groups. Logistic regression analysis adjustment for all covariates revealed that LDR plus Intralipid therapy produced significantly higher live birth rates (LBRs; 60%) compared to LDR alone (40% LBR); yet, the addition of prednisolone to GnRH agonist LDR (30% LBR) provided no additional live birth benefit.</p><p><strong>Conclusion: </strong>In this retrospective analysis, we showed Intralipid adjuvant treatment in combination with GnRH agonist therapy in adenomyosis patients undergoing IVF resulted in a LBR expected in women without adenomyosis using preimplantation genetic testing screened embryos. This benefit was not seen when using prednisolone as an adjuvant to GnRH agonist LDR. Future randomized clinical trials will be required to confirm the therapeutic benefit of Intralipid in combination with GnRH agonist therapy.</p>","PeriodicalId":75219,"journal":{"name":"Therapeutic advances in reproductive health","volume":null,"pages":null},"PeriodicalIF":3.1,"publicationDate":"2023-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/69/f8/10.1177_26334941231181258.PMC10288412.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9771486","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reversible interventions for menstrual management in adolescents and young adults with gender incongruence.","authors":"Rosemary Claire Roden","doi":"10.1177/26334941231158251","DOIUrl":"10.1177/26334941231158251","url":null,"abstract":"<p><p>The newly released <i>World Professional Association for Transgender Health Standards of Care, 8th Edition</i> specify that adolescents should be offered menstrual suppression as part of their treatment plans to suppress menses and alleviate dysphoria, provide contraception, or improve irregular bleeding on testosterone therapy. This is a review of current evidence-based options for reversible interventions for menstrual suppression in adolescents with gender dysphoria or incongruence. Shared decision-making should be used by the clinician at all times, and the clinician should be intentional in prioritizing the patient's stated needs and desires when offering interventions. No method should be withheld due to the experience of gender incongruence alone. Contraceptive options offering menstrual suppression include depot-medroxyprogesterone acetate, levonorgestrel intrauterine systems, progestin-only contraceptive pills, and combined hormonal contraceptives. Non-contraceptive options include norethindrone acetate, oral medroxyprogesterone acetate, gonadotropin-releasing hormone analogues/agonists, and danazol. Certain patients may also benefit from non-pharmacologic interventions, such as specialty menstrual underwear.</p><p><strong>Plain language summary: </strong><b>Using medicine to stop Menstrual periods in teens with gender incongruence</b> <b>Summary:</b> Newly released recommendations for the care of teens and young adults with gender dysphoria or incongruence specifically recommend using medications to get rid of menstrual periods if desired or medically necessary. Patients may ask for this to help improve dysphoria, as a feature they want in birth control, or simply because they do not want to have periods. Because temporarily getting rid of periods is something that doctors can do for any patient old enough to have periods, patients with gender dysphoria should also be able to have their periods temporarily stopped using medications if requested. Doctors should ensure that they always help the patient make a decision that is right for them instead of prescribing what they think is right without considering the patient's input. Options for temporarily getting rid of periods can include birth control, such as oral contraceptive pills, patches, or rings; intrauterine devices; or shots, and it can also be done with things that are not birth control, such a progesterone pills or puberty blockers. Finally, some patients may only need improved period hygiene with period underwear to feel better in their bodies.</p>","PeriodicalId":75219,"journal":{"name":"Therapeutic advances in reproductive health","volume":null,"pages":null},"PeriodicalIF":3.1,"publicationDate":"2023-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/8a/e3/10.1177_26334941231158251.PMC10017940.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9515578","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Emerging concepts in male contraception: a narrative review of novel, hormonal and non-hormonal options.","authors":"C Austin Service, Dhruv Puri, Tung-Chin Hsieh, Darshan P Patel","doi":"10.1177/26334941221138323","DOIUrl":"10.1177/26334941221138323","url":null,"abstract":"<p><p>Access to reliable contraception is a pillar of modern society. The burden of unintended pregnancy has fallen disproportionately on the mother throughout human history; however, recent legal developments surrounding abortion have sparked a renewed interest in male factor contraceptives beyond surgical sterilization and condoms. Modern efforts to develop reversible male birth control date back nearly a century and initially focused on altering the hypothalamic-pituitary-testes axis. These hormonal contraceptives faced multiple barriers, including systemic side effects, challenging dosing regimens, unfavorable routes of delivery, and the public stigma surrounding steroid use. Novel hormonal agents are seeking to overcome these barriers by limiting the side effects and simplifying use. Non-hormonal contraceptives are agents that target various stages of spermatogenesis; such as inhibitors of retinoic acid, Sertoli cell-germ cell interactions, sperm ion channels, and other small molecular targets. The identification of reproductive tract-specific genes associated with male infertility has led to more targeted drug development, made possible by advances in CRISPR and proteolysis targeting chimeras (PROTACs). Despite multiple human trials, no male birth control agents have garnered regulatory approval in the United States or abroad. This narrative review examines current and emerging male contraceptives, including hormonal and non-hormonal agents.</p>","PeriodicalId":75219,"journal":{"name":"Therapeutic advances in reproductive health","volume":null,"pages":null},"PeriodicalIF":3.1,"publicationDate":"2023-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9996746/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9102026","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment modalities for poor ovarian responders.","authors":"Federica Di Guardo,&nbsp;Nicola Pluchino,&nbsp;Panagiotis Drakopoulos","doi":"10.1177/26334941221147464","DOIUrl":"https://doi.org/10.1177/26334941221147464","url":null,"abstract":"Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). The term poor ovarian response (POR) was first introduced by the Bologna Criteria (BC), as a condition which includes at least two of the following features: advanced maternal age (⩾40 years), a previous POR with ⩽3 oocytes retrieved after conventional stimulation and/or an abnormal ovarian reserve test [i.e. antral follicle count (AFC) < 7 or anti-Müllerian hormone (AMH) < 1.1 ng/ml]. In the case of non-advanced maternal age and normal ovarian reserve test, POR is defined when a patient reports two episodes of POR following maximal ovarian stimulation.1 Although the BC represented a milestone in the field of in vitro fertilization (IVF),2 criticism about its substantial heterogeneity of the population may have prevented its widespread use in clinical practice. In this regard, a recent re-evaluation of these criteria has been proposed by the Poseidon Group (Patient-Oriented Strategies Encompassing IndividualizeD Oocyte Number)3 in order to overcome limitations of the BC. Some of the weaknesses of the BC are the ambiguity in defining risk factors, its substantial heterogeneity, the lack of accounting for oocyte quality, and other factors that can be associated with a low ovarian reserve.4–6 In this view, the Poseidon Group classification has been developed to better stratify the ‘low-prognosis patient’ by considering (1) qualitative and numerical parameters (e.g. expected aneuploidy rate and patient’s age); (2) ovarian reserve indicators (AFC and/or AMH); and (3) ovarian response to previous stimulation cycle, including four subgroups of patients: [Group 1: women younger than 35 years with AFC ⩾ 5 and AMH ⩾ 1.2; Group 2: women of age ⩾ 35 with AFC ⩾ 5 and AMH ⩾ 1.2; Group 3: women younger than 35 years old with AFC < 1 and AMH < 1.2 ng/ml; Group 4: ⩾35 with AFC < 1 and AMH < 1.2 ng/ml].","PeriodicalId":75219,"journal":{"name":"Therapeutic advances in reproductive health","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/42/64/10.1177_26334941221147464.PMC9880576.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10590510","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neurokinin receptor antagonists as potential non-hormonal treatments for vasomotor symptoms of menopause.","authors":"Melissa Conklin,&nbsp;Nanette Santoro","doi":"10.1177/26334941231177611","DOIUrl":"https://doi.org/10.1177/26334941231177611","url":null,"abstract":"<p><p>Vasomotor symptoms of menopause (VMS), otherwise known as hot flashes, can significantly impact women's quality of life. Up to 87% of women report hot flashes during or after their menopause transition, and can last for a median duration of 7.4 years. The current mainstay of treatment and the most effective treatment for VMS is hormone therapy with estrogen. However, hormone therapy is not without risk, and the discovery of an effective nonhormonal treatment option with neurokinin B receptor antagonists for VMS provides an encouraging and potentially practice-changing treatment option for all women. This review will discuss the pathophysiology and mechanism of action, as well as review the current compounds in development targeting the neurokinin receptors.</p>","PeriodicalId":75219,"journal":{"name":"Therapeutic advances in reproductive health","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/cb/38/10.1177_26334941231177611.PMC10302519.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9741931","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}